Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to ...

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price ...

Bright Futures Wealth Management LLC. cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 55.1% in the 4th ...

V Square Quantitative Management LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.9% in the 4th quarter, ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. Furthermore, revenue ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently sold shares of the company's stock. According to a recent SEC filing, Wolk sold 13,015 ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased ... that gives Medicare the power to negotiate drug prices. The first round of negotiations will target ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently executed significant stock transactions according to a recent SEC filing. On February 7, ...